Drug intelligence / Profile preview

H-CVAD + doxorubicin liposomal

Development stage: Unknown
Modality: Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous

Overview

A multi-agent chemotherapy regimen combining an H-CVAD backbone with liposomal doxorubicin (Doxil). H-CVAD refers to hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; in this regimen the conventional doxorubicin component is replaced or supplemented with pegylated liposomal doxorubicin to maintain anthracycline activity while potentially modifying toxicity and pharmacokinetics. The regimen has been studied in peripheral T-cell lymphomas as an investigational combination.

Brand names: Doxil
Other names: HCVIDDOXIL regimen

Targets

TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on H-CVAD + doxorubicin liposomal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H-CVAD + doxorubicin liposomal.

Explore the full profile